Role of Hypoxia Ans Sleep Fragmentation in Alzheimer's Disease. and Sleep Fragmentation. (NCT02814045) | Clinical Trial Compass
CompletedNot Applicable
Role of Hypoxia Ans Sleep Fragmentation in Alzheimer's Disease. and Sleep Fragmentation.
Spain144 participantsStarted 2015-11
Plain-language summary
Alzheimer's Disease (AD) is the most prevalent neurodegenerative disease, manifested as an initial deficit of episodic memory that evolves into a global cognitive and psychosocial dysfunction and which prevalence is increasing around the world. Sleep disturbance is frequent since early stages of the disease and sleep fragmentation had been demonstrated increase the production of amyloid peptide (AB) (main pathological hallmark) in non-demented population. Obstructive Sleep Apnea (OSA), which consist in intermittent hypoxia and sleep fragmentation, is a major health problem with multiple systemic effects and it's very prevalent in AD. However, the influence of this comorbidity on the cognitive evolution of AD patients remains unknown. The investigation of neurobiological markers and sleep recording may reveal potential mechanisms of neurodegeneration and explain the influence of sleep fragmentation and/or hypoxia on cognitive decline.
To fill those gaps, investigators will perform a multidisciplinary and translational project to assess the progression of symptoms in AD patients, diagnosis of sleep disturbance and new biomarkers of progression of the disease.
The present proposal is going to be developed by coordination of different expertises that will be range from the clinical research conducted by a medical neurologist, to the animal model and most molecular work, to be done by an experimented group in mouse work.
Who can participate
Age range50 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients diagnosed of mild probable AD according to NIA-AA criteria (MMSE\>20).
✓. Informed Consent Form signed by the patient (and/or if applicable the legal representative if different from the responsible caregiver) and the responsible caregiver.
✓. The patient has a knowledgeable and reliable caregiver who will accompany the patient to all clinic visits during the study.
✓. Absence of visual and hearing problems that, in the investigator's judgement, difficult for compliance with the study procedures.
Exclusion criteria
✕. Previous diagnosis of OSA.
✕. Severe Alzheimer's disease, other types of dementia or patients with mild Alzheimer's disease with current acetylcholinesterase inhibitors or memantine treatment.
✕. Presence of any previously diagnosed sleep disorder: narcolepsy, insomnia, chronic lack of sleep.
✕. Having serious comorbidities: cancer, excessive intake of alcohol (\>280 gr/week), severe depression, severe renal or hepatic insufficiency, severe cardiac or respiratory failure.
What they're measuring
1
Change from baseline in cognitive scores on the Disease Assessment Scale-cognitive at 12 months in patients with mild AD with and without OSA.
Timeframe: One year
Trial details
NCT IDNCT02814045
SponsorSociedad Española de NeumologÃa y CirugÃa Torácica
✕. Currently receiving an investigational drug or device.
✕. Patient or family declining to take part.
✕. Disabling drowsiness not justifiable by any other cause.
✕. The patient has MRI evidence of hydrocephalus, stroke, a space-occupying lesion, cerebral infection or any clinically significant central nervous system disease other than AD.